São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
Pharmacol Res. 2018 Mar;129:237-250. doi: 10.1016/j.phrs.2017.11.026. Epub 2017 Nov 22.
Adjuvants are substances used to enhance the efficacy of vaccines. They influence the magnitude and alter the quality of the adaptive immune response to vaccine antigens by amplifying or modulating different signals involved in the innate immune response. The majority of known adjuvants have been empirically identified. The limited immunogenicity of new vaccine antigens and the need for safer vaccines have increased the importance of identifying single, well-defined adjuvants with known cellular and molecular mechanisms for rational vaccine design. Depletion or functional inhibition of CD4CD25FoxP3 regulatory T cells (Tregs) by molecular adjuvants has become an emergent approach in this field. Different successful results have been obtained for specific vaccines, but there are still unresolved issues such as the risk of autoimmune disease induction, the involvement of cells other than Tregs and optimization for different conditions. This work provides a comprehensive analysis of current approaches to inhibit Tregs with molecular adjuvants for vaccine improvement, highlights the progress being made, and describes ongoing challenges.
佐剂是用于增强疫苗效力的物质。它们通过放大或调节参与固有免疫反应的不同信号,来影响疫苗抗原适应性免疫反应的幅度和改变其质量。大多数已知的佐剂都是通过经验确定的。新疫苗抗原的有限免疫原性和对更安全疫苗的需求,增加了确定具有已知细胞和分子机制的单一、明确佐剂的重要性,以便进行合理的疫苗设计。通过分子佐剂耗竭或功能抑制 CD4+CD25+FoxP3+调节性 T 细胞(Tregs)已成为该领域的一种新兴方法。针对特定疫苗已经取得了不同的成功结果,但仍存在一些未解决的问题,例如自身免疫疾病诱导的风险、除 Tregs 以外的细胞的参与以及针对不同条件的优化。这项工作全面分析了用分子佐剂抑制 Tregs 以改善疫苗的当前方法,强调了正在取得的进展,并描述了正在面临的挑战。